Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Reata Pharma (RETA)

Reata Pharma (RETA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,452,475
  • Shares Outstanding, K 33,604
  • Annual Sales, $ 26,520 K
  • Annual Income, $ -290,170 K
  • 60-Month Beta 1.61
  • Price/Sales 137.64
  • Price/Cash Flow N/A
  • Price/Book 15.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -2.10
  • Number of Estimates 3
  • High Estimate -1.98
  • Low Estimate -2.29
  • Prior Year -1.32
  • Growth Rate Est. (year over year) -59.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.00 +1.99%
on 09/25/20
117.00 -19.80%
on 09/23/20
-9.15 (-8.89%)
since 08/25/20
3-Month
92.00 +1.99%
on 09/25/20
168.50 -44.31%
on 06/26/20
-72.69 (-43.65%)
since 06/25/20
52-Week
73.38 +27.87%
on 10/02/19
257.96 -63.63%
on 02/05/20
+2.17 (+2.37%)
since 09/25/19

Most Recent Stories

More News
Reata Pharmaceuticals, Inc. (RETA) Down 6.2% Since Last Earnings Report: Can It Rebound?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RETA : 93.83 (-8.67%)
Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich's Ataxia at the American Academy of Neurology

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced the forthcoming presentation of efficacy and safety results from...

RETA : 93.83 (-8.67%)
XORTX Therapeutics Moves Toward Phase 3 Trials to Help with an "Orphan" Kidney Disease and COVID-19 Kidney Injuries

eResearch Corp. (www.eresearch.com) published a 33-page initiation equity Research Report on XORTX ...

RETA : 93.83 (-8.67%)
RGLS : 0.4800 (+4.14%)
XRX.CN : 0.140 (-9.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reata Pharmaceuticals, Inc. - RETA

Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com...

RETA : 93.83 (-8.67%)
SHAREHOLDER ALERT: Investigation of Reata Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) complied with federal securities laws. On August 10, 2020, Reata disclosed in its quarterly...

RETA : 93.83 (-8.67%)
Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts

Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.

EBS : 101.63 (+2.54%)
HZNP : 78.25 (+3.88%)
ABBV : 86.23 (+0.37%)
RETA : 93.83 (-8.67%)
Foot Locker, MGM rise; Reata, Kodak fall

NEW YORK (AP) — Stocks that moved heavily or traded substantially Monday:

SPG : 63.58 (+1.19%)
RETA : 93.83 (-8.67%)
NKLA : 19.46 (+1.88%)
MGM : 22.10 (+4.29%)
PPL : 26.47 (+1.53%)
FL : 32.80 (-0.21%)
KODK : 9.32 (+6.27%)
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.56% and 111.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?...

RETA : 93.83 (-8.67%)
Reata Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED FOR BARDOXOLONE

RETA : 93.83 (-8.67%)
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

NVAX : 113.56 (+10.86%)
HALO : 26.06 (+1.24%)
FOLD : 13.80 (-0.04%)
ICPT : 40.42 (+1.66%)
RETA : 93.83 (-8.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RETA with:

Business Summary

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address...

See More

Key Turning Points

2nd Resistance Point 107.89
1st Resistance Point 100.86
Last Price 93.83
1st Support Level 89.40
2nd Support Level 84.97

See More

52-Week High 257.96
Fibonacci 61.8% 187.45
Fibonacci 50% 165.67
Fibonacci 38.2% 143.89
Last Price 93.83
52-Week Low 73.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar